Autoantibody to MDM2: A potential serological marker of primary Sjogren’s syndrome

Yuan Liu; Xining Liao; Ying Wang; Shiju Chen; Yuechi Sun; Qingyan Lin; Guixiu Shi

doi:10.18632/oncotarget.14882

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Immunology:

Autoantibody to MDM2: A potential serological marker of primary Sjogren’s syndrome

Yuan Liu, Xining Liao, Ying Wang, Shiju Chen, Yuechi Sun, Qingyan Lin and Guixiu Shi _

PDF | HTML | How to cite

Oncotarget. 2017; 8:14306-14313. https://doi.org/10.18632/oncotarget.14882

Metrics: PDF 1945 views | HTML 2341 views | ?

Abstract

Yuan Liu1,*, Xining Liao2,*, Ying Wang3,*, Shiju Chen1, Yuechi Sun1, Qingyan Lin1 and Guixiu Shi1

1 Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China

2 Medical College, Xiamen University, Xiamen, Fujian, China

3 Department of Endocrinology, The ChengGong Hospital Affiliated to Xiamen University, Xiamen, Fujian, China

* Yuan Liu, Xining Liao and Ying Wang contribute equally to this study

Correspondence to:

Guixiu Shi, email:

Keywords: primary Sjogren’s syndrome; anti-MDM2 autoantibody; biomarker;Immunology and Microbiology Section; Immune response; Immunity

Received: September 27, 2016 Accepted: January 17, 2017 Published: January 28, 2017

Abstract

Introduction: Primary Sjogren’s Syndrome (pSS) is one of the autoimmune diseases characterized by polyclonal autoantibody production. The human homologue of the mouse double minute 2 (MDM2) is an important negative regulator of p53. Our previous study indicated that autoantibody to MDM2 can be detected in systemic lupus erythematosus patients. The purpose of this study is to study anti-MDM2 autoantibody in pSS patients.

Methods: Anti-MDM2 autoantibody in sera from 100 pSS patients and 74 normal controls was investigated by ELISA. Positive samples were further confirmed by western blotting. Expression of MDM2 in labial gland tissue from pSS patients and normal controls was checked by immunohistochemistry. The difference in clinical characteristics and laboratory findings between anti-MDM2 positive and anti-MDM2 negative pSS patients was analyzed.

Results: The presence of anti-MDM2 autoantibody in pSS patients was 21.0%, significantly higher than normal controls (5.40%). MDM2 was overexpressed in labial gland from pSS patients. pSS patients with positive anti-MDM2 were characterized by longer disease duration and more lymphocytes focal gathering in labial gland. Prevalence of anemia, thrombocytopenia and anti-SSB was significantly higher in pSS patients with anti-MDM2 autoantibody. Titer of anit-MDM2 was negatively associated with hemoglobin level, platelet count, complement 3 level and complement 4 level, positively associated with European Sjogren’s syndrome disease activity index (ESSDAI) and level of IgG.

Conclusions: Anti-MDM2 autoantibody may be used as a potential serological biomarker in pSS disease activity evaluation. Study on the role of anti-MDM2 or MDM2 in pSS may help us know the pathogenesis mechanism of pSS better.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14882

Publication Alerts

Research Papers: Immunology:

Autoantibody to MDM2: A potential serological marker of primary Sjogren’s syndrome

Abstract